Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259732 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL8485027 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL4549444 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL13026647 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL13224387 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL12092813 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL13381178 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL17167314 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL11961990 | 1.00 | LMNA (0.36) | LMNA | |
| SCHEMBL12601856 | 1.00 | LMNA (0.36) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2010-04-01 | — | — | US | disclosed |
| WO-2008041131-A2 | ANTICOAGULANT COMPOUNDS | ENDOTIS PHARMA (FR) | 2008-04-10 | — | — | WO | disclosed |
| WO-2008029278-A2 | CONJUGATES OF ANTITHROMBIN BINDING OLIGOSACCHARIDE DERIVATIVES AND THERAPEUTIC PROTEINS | ENDOTIS PHARMA S.A. (FR) | 2008-03-13 | — | — | WO | disclosed |
| EP-1886696-A1 | Conjugates of antithrombin binding oligosaccharide derivatives and therapeutic proteins | Endotis Pharma (FR) | 2008-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081708-A1 | ANTICOAGULANT COMPOUNDS | SERPINC1, F2, FUT5 | LMNA 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.